Evidence map›Paper›PMID 37602656›Full record

ArticleCancer medicine2023

Monitoring of gastrointestinal carcinoma via molecular residual disease with circulating tumor DNA using a tumor-informed assay.

Zining Qi, Yi Li, ZhengKun Wang, Xuerong Tan, Yixuan Zhou, Zhendong Li, Weirong Zhao, Xin Zheng, Jicheng Yao, Feng Li and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Zining QiDepartment of Gastrointestinal surgery, The First Hospital of Shanxi Medical University, Taiyuan, China.
Yi LiDepartment of Gastrointestinal surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
ZhengKun WangDepartment of Gastrointestinal surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Xuerong TanDepartment of Radiology, The Second Hospital of Dalian Medical University, Dalian, China.
Yixuan ZhouDepartment of Radiology, The Second Hospital of Dalian Medical University, Dalian, China.
Zhendong LiShanghai OrigiMed Co., Ltd, Shanghai, China.
Weirong ZhaoShanghai OrigiMed Co., Ltd, Shanghai, China.
Xin ZhengShanghai OrigiMed Co., Ltd, Shanghai, China.
Jicheng YaoShanghai OrigiMed Co., Ltd, Shanghai, China.
Feng LiShanghai OrigiMed Co., Ltd, Shanghai, China.
Weifeng WangShanghai OrigiMed Co., Ltd, Shanghai, China.ORCID 0000-0001-6559-7643
Zhizheng WangShanghai OrigiMed Co., Ltd, Shanghai, China.ORCID 0000-0001-9346-7184
Fei PangShanghai OrigiMed Co., Ltd, Shanghai, China.
Gang WangDepartment of General Surgery, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.
Weiguang GuDepartment of oncology, Nanhai People's Hospital, Foshan, China.
Shanghai Chengtou (China) · CNQingdao University · CNDalian Medical University · CNJiangsu Province Hospital · CNShanxi Medical University · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCirculating tumor DNA (ctDNA)-based minimal residual disease (MRD) detection, which can identify disease relapse ahead of radiological imaging, has shown promising performance. The objective of this study was to develop and validate OriMIRACLE S (Minimal Residual Circulating Nucleic Acid Longitudinal Detection in Solid Tumor), a highly sensitive and specific tumor-informed assay for MRD detection.

methodsTumor-specific somatic single nucleotide variants (SNVs) were identified via whole exome sequencing of tumor tissue and matched germline DNA. Clonal SNVs were selected using the OriSelector algorithm for patient-specific, multiplex PCR-based NGS assays in MRD detection. Plasma-free DNA from patients with gastrointestinal tumors prior to and following an operation, and during monitoring, were ultradeep sequenced.

resultsThe detection of three positive sites was sufficient to achieve nearly 100% overall sample level sensitivity and specificity and was determined by calculating binomial probability based on customized panels containing 21 to 30 variants. A total of 127 patients with gastrointestinal tumors were enrolled in our study. Preoperatively, MRD was positive in 18 of 26 patients (69.23%). Following surgery, MRD was positive in 24 of 82 patients (29.27%). The positivity rate for MRD was 33.33% (n = 18) for gastric adenocarcinoma and 32.26% (n = 62) for colorectal cancer. Twenty (20) of 59 patients (34.48%) experienced a change in MRD status over the monitoring period. Patients 8 and 31 responded to 3 cycles of systemic therapy, after which levels for all ctDNA dropped below the detection limit. Patient 53 was an example of using MRD to predict tumor metastasis. Patient 55 showed a weak response to treatments first and respond to new systemic therapy after tumor progression.

conclusionOur study identified a sensitive and specific clinical detection method for low frequency ctDNA, and explored the detection performance of this technology in gastrointestinal tumors.

Indexed as

CarcinomaCirculating Tumor DNAGastrointestinal NeoplasmsHumansNeoplasm Recurrence, LocalNeoplasm, ResidualCirculating Tumor DNAcirculating tumor DNAgastrointestinal carcinomamolecular residual diseasetumor metastasis

Identifiers

PMID37602656
PMCPMC10501225
OpenAlexW4386019182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.